Title

Synthesis, Characterization, and in vitro Studies of Vanadium-Containing Complexes for treatment of Breast Cancer

Description/Abstract

African American (AA) women have a significantly higher incidence and mortality from triple-negative breast cancer (TNBC) than any other racial group. The development of TNBC among Africa and Caribbean black women is 8-46% lower than among US AA women, suggesting an inherent difference in AA women and the need for non-hormone-based standard of care (SOC) chemotherapeutic agents. Vanadium-containing compounds are currently studied for their anti-cancer efficacy in many cancer types. We hypothesized that vanadium-containing complexes are more efficacious anti-cancer agents than the SOC treatment in all TNBC groups. Three vanadium-containing complexes [1] K[VO(O2)2(phen=1,10-phenanthroline)]●3H2O, [2][VO(sal-L-tryp = N-salicylidene-L-tryptophanate)(H2O)], [3] [VO(sal-L-tryp)(phen)]●H2O were synthesized and characterized via FTIR and UV-visible spectroscopies. The efficacy of the vanadium-containing complexes was assessed by the MTT viability assay using the AA TNBC cell line, HCC70. The 24H IC50 values were 69.0 µM, 43.2 µM, and 38.6 µM for complexes 1, 2, and 3, respectively. The 48H IC50 values were 31.2 µM, 4.7 µM, and 6.12 µM for these same complexes. These results demonstrated that these novel complexes decreased the growth of HCC70 cells in vitro and were more efficacious than previously determined SOC agents. IC50 values obtained on A431 and HFF cell lines were 40.1 µM and 80.2 µM, respectively. Ongoing studies investigate the anti-cancer potencies of these complexes in HCC1937 and the MDA-MB-231 VIM RFP TNBC cell lines relative to the SOC. In conclusion, these complexes show significant promise to inhibit breast cancer growth and may serve as a SOC for TNBC.

Presenting Author Name/s

Jasmine S. Clark

Faculty Advisor

Dr. Alvin A. Holder

Presentation Type

Poster

Disciplines

Inorganic Chemistry

Session Title

Poster Session

Location

Learning Commons, Atrium

Start Date

February 2020

End Date

February 2020

This document is currently not available here.

Share

COinS
 
Feb 8th, 8:00 AM Feb 8th, 12:30 PM

Synthesis, Characterization, and in vitro Studies of Vanadium-Containing Complexes for treatment of Breast Cancer

Learning Commons, Atrium

African American (AA) women have a significantly higher incidence and mortality from triple-negative breast cancer (TNBC) than any other racial group. The development of TNBC among Africa and Caribbean black women is 8-46% lower than among US AA women, suggesting an inherent difference in AA women and the need for non-hormone-based standard of care (SOC) chemotherapeutic agents. Vanadium-containing compounds are currently studied for their anti-cancer efficacy in many cancer types. We hypothesized that vanadium-containing complexes are more efficacious anti-cancer agents than the SOC treatment in all TNBC groups. Three vanadium-containing complexes [1] K[VO(O2)2(phen=1,10-phenanthroline)]●3H2O, [2][VO(sal-L-tryp = N-salicylidene-L-tryptophanate)(H2O)], [3] [VO(sal-L-tryp)(phen)]●H2O were synthesized and characterized via FTIR and UV-visible spectroscopies. The efficacy of the vanadium-containing complexes was assessed by the MTT viability assay using the AA TNBC cell line, HCC70. The 24H IC50 values were 69.0 µM, 43.2 µM, and 38.6 µM for complexes 1, 2, and 3, respectively. The 48H IC50 values were 31.2 µM, 4.7 µM, and 6.12 µM for these same complexes. These results demonstrated that these novel complexes decreased the growth of HCC70 cells in vitro and were more efficacious than previously determined SOC agents. IC50 values obtained on A431 and HFF cell lines were 40.1 µM and 80.2 µM, respectively. Ongoing studies investigate the anti-cancer potencies of these complexes in HCC1937 and the MDA-MB-231 VIM RFP TNBC cell lines relative to the SOC. In conclusion, these complexes show significant promise to inhibit breast cancer growth and may serve as a SOC for TNBC.